Cancer expert attacks drug company's funding of research paperBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39328.486100.DB (Published 06 September 2007) Cite this as: BMJ 2007;335:469
- Caroline White
A leading cancer epidemiologist has heavily criticised the funding and science of a report that compares different rates of cancer survival in 25 countries. The report linked cancer survival with access to new and innovative drugs.
The Karolinska 2 report, published earlier this year in the Annals of Oncology, concluded that access to cancer drugs affected survival and that the licensing process should be speeded up, with equitable access for all (2007;18(suppl 3):iii2-7).
But the epidemiologist Michel Coleman, who heads the cancer survival group of Cancer Research UK, has in the latest issue of the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial